ATE211654T1 - Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff - Google Patents

Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff

Info

Publication number
ATE211654T1
ATE211654T1 AT93922202T AT93922202T ATE211654T1 AT E211654 T1 ATE211654 T1 AT E211654T1 AT 93922202 T AT93922202 T AT 93922202T AT 93922202 T AT93922202 T AT 93922202T AT E211654 T1 ATE211654 T1 AT E211654T1
Authority
AT
Austria
Prior art keywords
group
antigens
protein
hybrid
carriers
Prior art date
Application number
AT93922202T
Other languages
English (en)
Inventor
James B Dale
Original Assignee
Univ Tennessee Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Corp filed Critical Univ Tennessee Res Corp
Application granted granted Critical
Publication of ATE211654T1 publication Critical patent/ATE211654T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
AT93922202T 1992-09-16 1993-09-15 Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff ATE211654T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94586092A 1992-09-16 1992-09-16
PCT/US1993/008704 WO1994006465A1 (en) 1992-09-16 1993-09-15 Antigen of hybrid m protein and carrier for group a streptococcal vaccine

Publications (1)

Publication Number Publication Date
ATE211654T1 true ATE211654T1 (de) 2002-01-15

Family

ID=25483630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93922202T ATE211654T1 (de) 1992-09-16 1993-09-15 Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff

Country Status (9)

Country Link
US (3) US6419932B1 (de)
EP (1) EP0618813B1 (de)
AT (1) ATE211654T1 (de)
AU (1) AU5128593A (de)
CA (1) CA2123580C (de)
DE (1) DE69331437T2 (de)
DK (1) DK0618813T3 (de)
IL (1) IL107026A0 (de)
WO (1) WO1994006465A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737521B1 (en) * 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
DK0618813T3 (da) * 1992-09-16 2002-03-11 Univ Tennessee Res Corp Antigen for M-hybridprotein og bærer for gruppe A streptococcal vaccine
AUPM885194A0 (en) * 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
NZ297142A (en) * 1994-10-24 2001-09-28 Texas A & M Univ Sys Oral immunisation and oral vaccines using edible transgenic plants comprising immunogenic agents such as E coli and cholera toxin antigens
US6287574B1 (en) * 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US20110166040A1 (en) * 1997-09-05 2011-07-07 Ibis Biosciences, Inc. Compositions for use in identification of strains of e. coli o157:h7
US6716433B1 (en) 1997-09-12 2004-04-06 University Of Tennessee Research Foundation Group a streptococcal vaccines
EP1801217A1 (de) * 1997-09-12 2007-06-27 The University of Tennessee Research Foundation Streptokokken-Impfstoffgruppe
CA2353802C (en) * 1998-12-22 2013-10-01 The University Of Tennessee Research Corporation New protective antigen of group a streptococci
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
EP1163000B1 (de) * 1999-03-19 2008-02-27 GlaxoSmithKline Biologicals S.A. Impfstoff gegen bakterielle antigene
US7256265B2 (en) 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0025170D0 (en) * 2000-10-13 2000-11-29 Smithkline Beecham Biolog Novel compounds
WO2004060278A2 (en) 2002-12-06 2004-07-22 Isis Pharmaceuticals, Inc. Methods for rapid identification of pathogens in humans and animals
US7718354B2 (en) 2001-03-02 2010-05-18 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
US20040121335A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents associated with host versus graft and graft versus host rejections
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
CA2447017A1 (en) * 2001-05-15 2002-11-21 Shire Biochem Inc. Moraxella(branhamella) catarrhalis antigens
US7407664B2 (en) 2001-05-18 2008-08-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Peptide vaccines against group A streptococci
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
CA2453062C (en) 2001-07-06 2013-04-02 Shire Biochem Inc. Group b streptococcus bvh-a5 antigens and corresponding dna fragments
CA2464527A1 (en) * 2001-10-26 2003-08-14 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US20040151737A1 (en) * 2003-02-05 2004-08-05 University Of Tennessee Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7709009B2 (en) 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
WO2005017093A2 (en) * 2003-08-15 2005-02-24 Id Biomedical Corporation Polypeptides of streptococcus pyogenes
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US20100129811A1 (en) * 2003-09-11 2010-05-27 Ibis Biosciences, Inc. Compositions for use in identification of pseudomonas aeruginosa
US20120122096A1 (en) 2003-09-11 2012-05-17 Rangarajan Sampath Compositions for use in identification of bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
EP2458619B1 (de) 2004-05-24 2017-08-02 Ibis Biosciences, Inc. Massenspektrometrie mit selektivem Ionfilter durch digitale Schwelle
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
WO2006094238A2 (en) 2005-03-03 2006-09-08 Isis Pharmaceuticals, Inc. Compositions for use in identification of adventitious viruses
WO2007014045A2 (en) 2005-07-21 2007-02-01 Isis Pharmaceuticals, Inc. Methods for rapid identification and quantitation of nucleic acid variants
EP1931779A4 (de) 2005-10-04 2009-07-29 Inimex Pharmaceuticals Inc Neue peptide zur behandlung und vorbeugung immunverwandter störungen, einschliesslich behandlung und vorbeugung durch modulation angeborener immunität
WO2007118222A2 (en) 2006-04-06 2007-10-18 Ibis Biosciences, INC Compositions for the use in identification of fungi
WO2008143627A2 (en) 2006-09-14 2008-11-27 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
JP2010505395A (ja) * 2006-10-04 2010-02-25 イニメックス ファーマシューティカルズ インコーポレイテッド 先天免疫を調節することによる感染の処置および予防を含む、免疫関連疾患障害の処置および予防のための新規ペプチド
BRPI0604997A (pt) 2006-11-30 2007-05-22 Fundacao Zerbini vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção
US9289485B2 (en) 2006-11-30 2016-03-22 Luiza Guilherme Guglielmi Therapeutic application of S. pyogenes C-terminal peptide
US8871471B2 (en) 2007-02-23 2014-10-28 Ibis Biosciences, Inc. Methods for rapid forensic DNA analysis
US20100291544A1 (en) * 2007-05-25 2010-11-18 Ibis Biosciences, Inc. Compositions for use in identification of strains of hepatitis c virus
WO2008151023A2 (en) 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
WO2009038840A2 (en) * 2007-06-14 2009-03-26 Ibis Biosciences, Inc. Compositions for use in identification of adventitious contaminant viruses
WO2009131728A2 (en) * 2008-01-29 2009-10-29 Ibis Biosciences, Inc. Compositions for use in identification of picornaviruses
WO2009155103A2 (en) * 2008-05-30 2009-12-23 Ibis Biosciences, Inc. Compositions for use in identification of tick-borne pathogens
WO2009151982A1 (en) * 2008-05-30 2009-12-17 Ibis Biosciences, Inc. Compositions for use in identification of francisella
US20110151437A1 (en) * 2008-06-02 2011-06-23 Ibis Biosciences, Inc. Compositions for use in identification of adventitious viruses
US8550694B2 (en) 2008-09-16 2013-10-08 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
EP2344893B1 (de) 2008-09-16 2014-10-15 Ibis Biosciences, Inc. Mikroplatten-handhabungssysteme und verfahren
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US20110200985A1 (en) * 2008-10-02 2011-08-18 Rangarajan Sampath Compositions for use in identification of herpesviruses
US20110189687A1 (en) * 2008-10-02 2011-08-04 Ibis Bioscience, Inc. Compositions for use in identification of members of the bacterial genus mycoplasma
WO2010039848A2 (en) * 2008-10-03 2010-04-08 Ibis Biosciences, Inc. Compositions for use in identification of streptococcus pneumoniae
US20110183344A1 (en) * 2008-10-03 2011-07-28 Rangarajan Sampath Compositions for use in identification of clostridium difficile
US20110190170A1 (en) * 2008-10-03 2011-08-04 Ibis Biosciences, Inc. Compositions for use in identification of antibiotic-resistant bacteria
WO2010039870A1 (en) * 2008-10-03 2010-04-08 Ibis Biosciences, Inc. Compositions for use in identification of neisseria, chlamydia, and/or chlamydophila bacteria
US20110183343A1 (en) * 2008-10-03 2011-07-28 Rangarajan Sampath Compositions for use in identification of members of the bacterial class alphaproteobacter
EP2356135B1 (de) 2008-11-05 2017-10-25 Wyeth LLC Immunogene multikomponentenzusammensetzung zur prävention einer erkrankung mit beta-hämolytischen streptokokken (bhs)
EP2396803A4 (de) 2009-02-12 2016-10-26 Ibis Biosciences Inc Ionisationssondenanordnungen
WO2010104798A1 (en) 2009-03-08 2010-09-16 Ibis Biosciences, Inc. Bioagent detection methods
WO2010114842A1 (en) 2009-03-30 2010-10-07 Ibis Biosciences, Inc. Bioagent detection systems, devices, and methods
WO2011008971A1 (en) 2009-07-17 2011-01-20 Ibis Biosciences, Inc. Lift and mount apparatus
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
WO2011014811A1 (en) 2009-07-31 2011-02-03 Ibis Biosciences, Inc. Capture primers and capture sequence linked solid supports for molecular diagnostic tests
EP3098325A1 (de) 2009-08-06 2016-11-30 Ibis Biosciences, Inc. Basenzusammensetzungen ohne massenbestimmung zur nukleinsäureerkennung
US20110065111A1 (en) * 2009-08-31 2011-03-17 Ibis Biosciences, Inc. Compositions For Use In Genotyping Of Klebsiella Pneumoniae
US9890408B2 (en) 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification
WO2011115840A2 (en) * 2010-03-14 2011-09-22 Ibis Biosciences, Inc. Parasite detection via endosymbiont detection
EP2720706B1 (de) 2011-06-17 2020-08-05 University of Tennessee Research Foundation Polyvalenter streptococcus-gruppe-a-impfstoff
AU2014214613A1 (en) 2013-02-11 2015-08-13 University Of Tennessee Research Foundation Group A streptococcal M-related proteins and methods of use
CL2013002782A1 (es) * 2013-09-27 2014-04-25 Univ Pontificia Catolica Chile Formulación inmunogénica para inducir la respuesta inmune en un sujeto que comprende una mezcla de bacterias no patógenas que expresan cada una un segmento hipervariable de la proteína m de diferentes streptococcus pyogenes; uso de la formulación para producir una vacuna; método para producir vacuna

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1200773A (en) * 1980-02-29 1986-02-18 William J. Rutter Expression linkers
US4284537A (en) * 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4521334A (en) 1982-07-27 1985-06-04 The University Of Tennesse Research Corporation Synthetic polypeptide fragments
US4454121A (en) 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US4597967A (en) 1982-07-27 1986-07-01 The University Of Tennessee Research Corp. Synthetic polypeptide fragments
US4886663A (en) * 1983-01-03 1989-12-12 Scripps Clinic And Research Foundation Synthetic heat-stable enterotoxin polypeptide of Escherichia coli and multimers thereof
US4919930A (en) * 1983-06-10 1990-04-24 University Of Tennessee Research Corporation Synthetic M proteins-streptococci type 5
US4784948A (en) * 1983-08-10 1988-11-15 The Rockefeller University Production of streptococcal m protein immunogens and molecular probes
US5149657A (en) * 1984-09-13 1992-09-22 Enzon Labs Inc. Escherichia coli expression vector encoding bioadhesive precursor protein analogs comprising three to twenty repeats of the decapeptide (Ala-Lys-Pro-Ser-Tyr-Pro-Pro-Thr-Tyr-Lys)
US4705684A (en) 1985-05-31 1987-11-10 The University Of Tennessee Research Corporation Synthetic M proteins - streptococci type 6
US5124153A (en) * 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
EP0446313B1 (de) * 1989-08-25 1996-07-31 Biotechnology Australia Pty. Ltd. Fusionsproteine bestehend aus TraTp und mindestens einem LHRH-Analog
EP0491859A4 (en) * 1989-09-13 1992-10-07 Ml Technology Ventures, L.P. Treponema hyodysenteriae antigens having a molecular weight of 39kda and dna encoding therefor
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
WO1993021220A1 (en) * 1992-04-08 1993-10-28 The Council Of The Queensland Institute Of Medical Research Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection
US5279937A (en) * 1992-04-30 1994-01-18 Detechnology Canada Use of macroglobulins to improve the signal-to-background ratio in affinity binding assays
ATE348175T1 (de) * 1992-07-17 2007-01-15 Dana Farber Cancer Inst Inc Method eder intrazellularen bindung von zielgerichteten molekülen
DK0618813T3 (da) * 1992-09-16 2002-03-11 Univ Tennessee Res Corp Antigen for M-hybridprotein og bærer for gruppe A streptococcal vaccine
ATE214601T1 (de) * 1992-09-16 2002-04-15 Univ Tennessee Res Corp Rekombinantes vielwertiges m-protein-vakzin
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US6716433B1 (en) * 1997-09-12 2004-04-06 University Of Tennessee Research Foundation Group a streptococcal vaccines
CA2464527A1 (en) * 2001-10-26 2003-08-14 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use

Also Published As

Publication number Publication date
CA2123580A1 (en) 1994-03-21
EP0618813A4 (en) 1997-05-21
EP0618813B1 (de) 2002-01-09
US20070053937A1 (en) 2007-03-08
US6419932B1 (en) 2002-07-16
CA2123580C (en) 2005-04-26
DE69331437T2 (de) 2002-09-05
WO1994006465A1 (en) 1994-03-31
US20020176863A1 (en) 2002-11-28
IL107026A0 (en) 1993-12-28
EP0618813A1 (de) 1994-10-12
DK0618813T3 (da) 2002-03-11
AU5128593A (en) 1994-04-12
DE69331437D1 (de) 2002-02-14
US7074416B2 (en) 2006-07-11

Similar Documents

Publication Publication Date Title
ATE211654T1 (de) Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff
DK0625043T3 (da) Vaccine med rekombinant multivalent M-protein
Beachey et al. Type-specific protective immunity evoked by synthetic peptide of Streptococcus pyogenes M protein
Svehag et al. THE FORMATION AND PROPERTIES OF POLIOVIRUS-NEUTRALIZING ANTIBODY: II. 19S and 7S Antibody Formation: Differences in Antigen Dose Requirement for Sustained Synthesis, Anamnesis, and Sensitivity to X-Irradiation
Robinson et al. Group A streptococcal M proteins: virulence factors and protective antigens
NO883763D0 (no) Terapeutiske blandinger mot streptokokkinfeksjoner, transformerte verter, fremgangsmaater ved immunisering og genespleisingsprodukter.
EP0692031A4 (de) Heterologe antigene in stämmen zur impfung mit lebendzellen
EP0787139A4 (de) Synthetische peptide und impfstoffe welche diese beinhalten
Dale et al. Heterogeneity of type-specific and cross-reactive antigenic determinants within a single M protein of group A streptococci.
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
Jarrett et al. Antibody response and virus survival in cats vaccinated against feline leukaemia
EP0837692A4 (de)
NO964863L (no) Kloning av ikke-IgA-Fc-bindende former av <beta>-antigenene fra streptokokker i gruppe B
Falcoff et al. Lymphocyte stimulation and interferon induction by 7 S anti‐human lymphocyte globulins and their uni‐and divalent fragments
ATE72400T1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
Ayakawa et al. Heart cross-reactive antigens of mutans streptococci share epitopes with group A streptococci and myosin.
GB2227936A (en) Vaccine against brucella abortus
Cox et al. Secretory antibody response to local injection of soluble or particulate antigens in rats
Luo et al. Interleukin-10 enhances immune responses to pneumococcal polysaccharides and sheep erythrocytes in young and aged mice
Schöller et al. Dental caries in gnotobiotic rats immunized with purified glucosyltransferase from Streptococcus sanguis
Ohmann et al. Secondary in vitro B lymphocyte (antibody) response to microbial antigens: use in appraisal of vaccine immunogenicity and cytokine immunoregulation
Moro et al. Symposium Report: Sixth International Congress of Mucosal Immunology: Dental Caries Vaccines-July 23rd, 1990.
Larsson et al. Vaccination with highly purified cell surface proteins confers protection against experimental group B streptococcal infection
ATE175357T1 (de) Empfängnisverhütender impfstoff
Ito et al. Gamma interferon production in allogeneic stimulation: antigenicity that is sufficient to cause interferon production

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties